C-Rad AB (LTS:0R44) EBIT: kr47.3 Mil (TTM As of Mar. 2026)


LTS:0R44 C-Rad AB LTS:0R44
83 GF Score
Price kr35.90
GF Value kr33.44
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is C-Rad AB EBIT?

C-Rad AB LTS:0R44 83 EBIT is kr47.3 Mil as of Mar. 2026. GuruFocus rates LTS:0R44 with a GF Score™ of 83/100 and a GF Value™ of kr33.44 (Fairly Valued). The stock has 4 warning signs investors should review.

C-Rad AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr12.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr47.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. C-Rad AB's annualized ROC % for the quarter that ended in Mar. 2026 was 12.04%. C-Rad AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 44.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. C-Rad AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.17%.


C-Rad AB  (LTS:0R44) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

C-Rad AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=48 * ( 1 - 22.38% )/( (283.763 + 334.9)/ 2 )
=37.2576/309.3315
=12.04 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=500.792 - 45.809 - ( 171.22 - max(0, 141.769 - 438.019+171.22))
=283.763

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

C-Rad AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=48/( ( (23.701 + max(69.524, 0)) + (23.1 + max(97.6, 0)) )/ 2 )
=48/( ( 93.225 + 120.7 )/ 2 )
=48/106.9625
=44.88 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(157.709 + 45.712 + 7.872) - (45.809 + 0 + 95.96)
=69.524

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(187 + 51 + 0) - (30.1 + 0 + 110.3)
=97.6

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

C-Rad AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=47.3/1134.091
=4.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C-Rad AB EBIT Related Terms


C-Rad AB EBIT Historical Data

* Premium members only.

The historical data trend for C-Rad AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C-Rad AB EBIT Chart

C-Rad AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.91 21.90 44.30 80.06 16.77

C-Rad AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.10 8.50 21.40 5.40 12.00

LTS:0R44 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, C-Rad AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C-Rad AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where C-Rad AB's EV-to-EBIT falls into.


LTS:0R44
83GF Score
C-Rad AB LTS:0R44
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C-Rad AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr47.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr47.3 Mil mean?
C-Rad AB (LTS:0R44) has a EBIT of kr47.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on C-Rad AB.
Is C-Rad AB's EBIT too high?
C-Rad AB's current EBIT is kr47.3 Mil. Overall, C-Rad AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's EBIT compare to ABT and SYK?
C-Rad AB's EBIT of kr47.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on C-Rad AB. C-Rad AB's current EBIT is kr47.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.44, compared to a current price of kr35.90 — trading 7.4% above its estimated fair value. The current EBIT is kr47.3 Mil. C-Rad AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current EBIT is kr47.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C-Rad AB (LTS:0R44) Overvalued in 2026?

Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued. The current stock price of kr35.90 is trading 7.4% above its estimated GF Value™ of kr33.44. GuruFocus considers C-Rad AB to be Fairly Valued.

Key valuation signals for LTS:0R44:

  • EBIT: kr47.3 Mil
  • GF Value™: kr33.44 vs. price of kr35.90 (7.4% above fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


C-Rad AB Business Description

Other Exchanges CRAD B:Sweden24C:Germany
Address Sjukhusvagen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
83GF Score

Get the complete analysis for LTS:0R44

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr35.90
Price
kr33.44
GF Value